Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.
about
Targeting RTK Signaling Pathways in CancerTargeting tumor-stromal interactions in bone metastasisCombination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft modelOckham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerRoles of c-Met and RON kinases in tumor progression and their potential as therapeutic targetsReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersThe decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiationEpigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapiesCo-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patientsMatriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcomaHigh Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancerA Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosisTargeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancerProfiling phospho-signaling networks in breast cancer using reverse-phase protein arraysKnockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines.Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes.Growth factor signaling in metastasis: current understanding and future opportunities.Systemic therapies in hepatocellular carcinoma: present and future.cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?Tivantinib: critical review with a focus on hepatocellular carcinoma.Trends in the development of MET inhibitors for hepatocellular carcinoma.Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma.Systematic Identification, Characterization and Target Gene Analysis of microRNAs Involved in Osteoarthritis Subchondral Bone Pathogenesis.Hematopoietic Stem Cell-derived Adipocytes Promote Tumor Growth and Cancer Cell Migration.High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancerFunction of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.Cancer Stem Cells, Bone and Tumor Microenvironment: Key Players in Bone Metastases.
P2860
Q26781278-DA582280-F997-476C-B08E-BAB790435D29Q27024561-00EFFA9C-7BCC-4539-8883-A994DC98E32CQ27302940-45FD0B7E-ABA1-408A-8345-B9B5A4F049F6Q28067777-591E2DA0-D1CB-41EA-BD54-FE06CFB29FEBQ28081193-B455F86F-8D3F-466B-82E3-01C0272F5FFAQ28082793-2FF018D8-6BD2-4372-BC87-CCE7DB485837Q30534479-C56C8808-D323-4037-98C3-7F7D094159D1Q31118547-7DC61F9E-0CE9-4473-A34C-B667F7DD6A07Q33895113-D44C71D8-03E9-4DE8-AC3E-AF84E6530C06Q34483478-C604CB80-4B92-4620-BA64-874558C1C3D2Q34854941-C3A0DD1D-9C51-41EC-8099-882FF7B4770EQ35214544-7601DDFC-023D-49E0-A0A1-F0ED2474C4AFQ35904618-5F64658A-1496-4DEA-A047-B4D2D4487E08Q36162776-70552BD3-4D9B-438E-A57E-61C3FC7E147FQ36184256-B36CC394-E3AB-4007-A349-62984196B5A4Q36557901-2069A071-B1ED-423A-8FC4-340CA5534445Q36567735-8ECA2994-587D-494E-B59A-1CDB40DC2734Q36574080-443A90D7-FBD9-4610-A70F-D8D20B94E7F7Q36897569-E68BF17A-9C43-4104-BA2F-1EB27DC7BE42Q37275734-7782B56A-8B23-491C-9F6D-7A6A0B6DBF0BQ37427337-00B86644-02CC-42D5-82CE-820FACF1A2C1Q37564471-45222ADC-0B84-459B-8C98-8A156AC85787Q38018675-E391EEC1-A8DF-4667-B915-537D32571E2BQ38019410-CCC21B00-AD4B-4940-8E06-01F5907B1A01Q38150875-295A882C-12AA-4E33-B2AA-11EBC8D143EDQ38236096-D0D3CC32-135E-4812-996A-BE4064ABA225Q38259343-C86705BE-B559-471C-9B61-273008C165B1Q38777675-C02DA4D9-8CE2-456F-86F9-65DB444638EAQ38844872-0D32C1D8-7AE8-4EF3-AEDE-1035000258E7Q39466467-7173DA7B-1A25-42FA-BCB0-E0598DB62E12Q39947211-61553240-B234-4F50-9926-4258AAEB5DDFQ42370129-22424C54-FDCC-4D58-8D0A-D543C8B39B24Q42414387-2D6F801E-FE71-4F07-A7FD-BFB0DEE43304Q49887893-C3318644-850D-478F-B1D9-BB8B19DC3488Q50027179-1D6BF5A5-567C-4129-8839-192A4E54D23E
P2860
Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Breast cancer-derived bone met ...... 97) and shRNA c-MET knockdown.
@en
Breast cancer-derived bone met ...... fic c-MET inhibitor tivantinib
@nl
type
label
Breast cancer-derived bone met ...... 97) and shRNA c-MET knockdown.
@en
Breast cancer-derived bone met ...... fic c-MET inhibitor tivantinib
@nl
prefLabel
Breast cancer-derived bone met ...... 97) and shRNA c-MET knockdown.
@en
Breast cancer-derived bone met ...... fic c-MET inhibitor tivantinib
@nl
P2093
P1476
Breast cancer-derived bone met ...... 97) and shRNA c-MET knockdown.
@en
P2093
Dennis S France
Francesca Dalò
Giovanni Abbadessa
Sara Previdi
P304
P356
10.1158/1535-7163.MCT-11-0277
P577
2011-10-25T00:00:00Z